Holen Sie sich die Stockscreener-App
123.34
0.84%
-1.0265
Schlusskurs vom Vortag:
$124.37
Offen:
$122.02
24-Stunden-Volumen:
455.55K
Relative Volume:
0.25
Marktkapitalisierung:
$25.01B
Einnahmen:
$5.36B
Nettoeinkommen (Verlust:
$1.43B
KGV:
17.44
EPS:
7.0718
Netto-Cashflow:
$1.42B
1W Leistung:
-3.63%
1M Leistung:
+3.19%
6M Leistung:
+21.78%
1J Leistung:
+45.76%
1-Tages-Spanne:
$121.61
$123.79
1-Wochen-Bereich:
$121.61
$130.80
52-Wochen-Spanne:
$81.09
$132.60
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
123.37 | 25.79B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
543.43 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.84 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,029.48 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.66 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.10 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte president Pablo Cagnoni sells $1.36m of INCY shares By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years - Benzinga
Insider Selling: Incyte (NASDAQ:INCY) Insider Sells $1,356,173.56 in Stock - MarketBeat
Incyte Corp's R&D Head Pablo J. Cagnoni Sells 10,801 Shares via 10b5-1 Trading Plan - Kalkine Media
Incyte (INCY) R&D head sells 10,801 shares, holds 183,200 in awards - Stock Titan
INCY Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Incyte (INCY) Quarter in Focus: The EPS Result Is Above Expectation for the Current Session; Stock Move: The Market Price Advances 4.05% on the DayRevenue Guidance Update - vinanet.vn
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $150 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on cancer trial data - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
Incyte (NASDAQ:INCY) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on cancer trial data By Investing.com - Investing.com UK
Canaccord Genuity Initiates Incyte at Buy With $152 Price Target - marketscreener.com
DCF Advisers LLC Takes Position in Incyte Corporation $INCY - MarketBeat
BlackRock Inc. Takes $2.04 Billion Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation: Target Price Consensus and Analysts Recommendations | ICY | US45337C1027 - marketscreener.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
US FDA approves Regeneron's rare bone disorder drug - marketscreener.com
INCY Looks 19.9% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Incyte (INCY) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading - Vinanet
State of Wyoming's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Maintained by Piper Sandler -- Price Target Raised to $130 - GuruFocus
Global Vitiligo Foundation Applauds Incyte’s "Moments of Clarity" Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness - Yahoo Finance
Incyte stock holds at the $120 mark as strong quarterly earnings support valuation - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
State of Wyoming Acquires New Holdings in Incyte Corporation $INCY - MarketBeat
LTS:0J9P EV-to-OCF: 10.03 — 48% Below Median - GuruFocus
55,370 Shares in Incyte Corporation $INCY Bought by Summit Global Investments - MarketBeat
Baird Chautauqua Global Growth Fund's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corp's Pablo J. Cagnoni Sells 10,803 Shares Under Rule 10b5-1 Plan in August 2026 - Kalkine Media
Incyte Corp (INCY) R&D chief sells 10,803 shares under Rule 10b5-1 plan - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Incyte stock gains support as Q2 2026 sales surge and guidance rises - AD HOC NEWS
Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating - marketscreener.com
Incyte Sales Growth Drives Share Price Gains - FXEmpire
Insight Wealth Strategies LLC Acquires New Position in Incyte Corporation $INCY - MarketBeat
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp (HAM:ICY) Stock Price, Trades & News - GuruFocus
Incyte Corporation (NASDAQ:INCY): What Could Drive Shares Next? - Kalkine Media
Incyte (INCY) Short Interest & Short Float | Updated Aug 2026 $INCY - MarketBeat
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bank of America Corp DE Sells 87,913 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Finviz
Incyte Corp (INCY) R&D head sells 10,640 shares in plan trade - Stock Titan
Incyte Corp (INCY) EVP sells 2,207 shares after option exercise - Stock Titan
Incyte Corp (ICY.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
1.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):